Overview of microneedle system: a third generation transdermal drug delivery approach

Nandagopal, M. S. Giri; Antony, Rahul; Rangabhashiyam, S.; Sreekumar, Nidhin; Selvaraju, N.

doi:10.1007/s00542-014-2233-5

Cited by 47 publications

(21 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rats in the oral group were fasted overnight, and then intragastrically administered pulverized Sifrol ® with the aid of water immediately after each blood sampling at 0, 8,16,24,32,40,48,56,64,72,80,88,96,104,112,120,128,136,144,152, and 160 h. Each dose was equal to 0.10 mg/kg PPX, and 21 doses were administrated in total. Rats in the transdermal group were treated with a PPX patch (0.6 cm 2 , approximately 1.2 mg PPX) at 0 h and removed at 168 h. Two days before patch application, abdominal hair of rats was removed by a razor, and the skin was carefully cleaned with warm water to avoid any adhesion problems caused by residues on the skin.…”

Section: In Vivo Pharmacokinetic Study In Ratsmentioning

confidence: 99%

“…Therefore, a better delivery route for PPX is in demand. Transdermal drug delivery system (TDDS) can continuously deliver drugs for a prolonged period of time to maintain relatively steady plasma drug concentration, thereby reducing the frequency of medication (15,16). In addition, delivery of drugs through skin can avoid the influence of gastrointestinal tract on the absorption of drugs, greatly improving patient compliance (17).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a Prolonged-Release Pramipexole Transdermal Patch: In Vitro and In Vivo Evaluation

Sun

et al. 2016

AAPS PharmSciTech

View full text Add to dashboard Cite

The current study aimed to develop a prolonged-release pramipexole (PPX) transdermal patch for the treatment of Parkinson's disease. Permeation parameters of PPX were investigated using human cadaver skin. Pramipexole patches were prepared using DURO-TAK pressure-sensitive-adhesive (PSA) and evaluated for drug stability, drug loading, in vitro drug release, and in vitro permeation through mouse skin. The results indicated that blends of DURO-TAK 87-2852 and DURO-TAK 87-2510 were suitable for creating a prolonged-release PPX patch due to their advantages in drug release, drug loading, and stability. The final formulation consisted of 87-2852/87-2510 (70:30), 10% PG, and 15% PPX and showed a cumulative permeation amount of 1497.19 ± 102.90 μg/cm with a continuous flux over 6.0 μg/(cm·h) across human cadaver skin for 7 days. In vivo studies in rats indicated that PPX patch produced a significantly longer (p < 0.001) half-life (t , 75.16 ± 17.37 h) and mean residence time (MRT, 135.89 ± 24.12 h) relative to oral tablets (Sifrol) and had a relative bioavailability of 51.64 ± 21.32%. Therefore, this study demonstrated the feasibility of developing a prolonged-release PPX patch, which proposed the potential to serve as an alternate to conventional oral tablets and may therefore improve patient compliance.

show abstract

Section: In Vivo Pharmacokinetic Study In Ratsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development of a Prolonged-Release Pramipexole Transdermal Patch: In Vitro and In Vivo Evaluation

Sun

et al. 2016

AAPS PharmSciTech

View full text Add to dashboard Cite

show abstract

“…A number of review papers have also discussed specific technologies, e.g. various methods to fabricate MNs, or the devices that are currently being used or are likely to be used in clinical trials (Giri Nandagopal et al, 2014;Jain et al, 2014). Indeed, one can safely assume that the most significant aspects of MNs research have been discussed in review or research papers.…”

Section: Dd Routesmentioning

confidence: 99%

Microneedles for drug delivery: trends and progress

2014

View full text Add to dashboard Cite

In recent years, there has been a surge in the research and development of microneedles (MNs), a transdermal delivery system that combines the technology of transdermal patches and hypodermic needles. The needles are in the hundreds of micron length range and therefore allow relatively little or no pain. For example, biodegradable MNs have been researched in the literature and have several advantages compared with solid or hollow MNs, as they produce non-sharp waste and can be designed to allow rapid or slow release of drugs. However, they also pose a disadvantage as successful insertion into the stratum corneum layer of the skin relies on sufficient mechanical strength of the biodegradable material. This review looks at the various technologies developed in MN research and shows the rapidly growing numbers of research papers and patent publications since the first invention of MNs (using time series statistical analysis). This provides the research and industry communities a valuable synopsis of the trends and progress being made in this field.

show abstract

“…Especially, MNs are considered to be the most powerful technology for vaccine delivery in developing countries [21]. The details of the functions and applications of MNs can be found in some comprehensive reviews [4,11,[22][23][24], and the fabrication technologies of MNs can also been found in some review papers [4,8,11,25]. In this review, however, we will discuss some fundamental problems that may influence the integrated properties of MNs.…”

Section: Introductionmentioning

confidence: 99%

Microneedle, bio-microneedle and bio-inspired microneedle: A review

2017

Journal of Controlled Release

342

198

View full text Add to dashboard Cite

Microneedles (MNs) are micro-scale needles used for drug delivery and other targets. Micro-scale size endows them with many advantages over hypodermic needles, including painlessness, minimal invasiveness and convenient operation, but it may also lead to risk of mechanical failures, which should be prevented in the clinical applications of MNs. The objective of this review is mainly to introduce studies on the mechanics problems with respect to MNs. Firstly, the basic knowledge of MNs is introduced in brief, so that readers can understand the basic characteristics of MNs. Secondly, researches on inserting behavior and mechanical performances of MNs are discussed. Thirdly, literatures on the drug delivery and the pain resulted from the insertion of MNs are overviewed. Finally, some bio-microneedles and bio-inspired MNs are introduced.

show abstract

Overview of microneedle system: a third generation transdermal drug delivery approach

Cited by 47 publications

References 143 publications

Development of a Prolonged-Release Pramipexole Transdermal Patch: In Vitro and In Vivo Evaluation

Development of a Prolonged-Release Pramipexole Transdermal Patch: In Vitro and In Vivo Evaluation

Microneedles for drug delivery: trends and progress

Microneedle, bio-microneedle and bio-inspired microneedle: A review

Contact Info

Product

Resources

About